E104 (compound 1), a selective TLR7 agonist, exhibits potent anticancer activity when delivered via antibody-drug conjugate (ADC) technology. It effectively activates mouse macrophages and human peripheral blood mononuclear cells (hPBMCs) [1].

Compound 17b, a TLR7 agonist also known as TLR7 agonist 14, exhibits high potency with an EC50 of 18 nM. It effectively activates mouse macrophages and human peripheral blood mononuclear cells (hPBMCs) at low-nanomolar concentrations [1].

Flavone glycoside from Robinia with antibacterial and diuretic properties; derived from kaempferol.The ability of robinin to reverse the multidrug resistance of the human colon cancer cell line Colo 320 expreβing MDR1/LRP was explored by monitoring their uptake of Rhodamine 123, but was shown to have minimal effect. Robinin (NSC-9222) was detected in lysates of the human breast cancer cell line MCF-7 using liquid chromatography-tandem maβ spectrometry.

TLR7 agonist 15 (compound 16b) is a potent activator of mouse macrophages and hPBMCs, demonstrating an EC50 of 18 nM. It induces robust responses at low-nanomolar concentrations [1].

LRRK2-IN-3 is a potent, selective, orally active LRRK2 inhibitor that crosses the blood-brain barrier with an IC50 value of 0.6 nM in hPBMCs. LRRK2-IN-3 can be used to study Parkinson's disease.

TLR7 agonist 16 (compound 16d) is a potent activator of TLR7 with an EC50 value of 18 nM. It effectively triggers the activation of both mouse macrophages and human peripheral blood mononuclear cells (hPBMCs) at low-nanomolar levels [1].